AAPL299.11+2.10 (+0.71%) ▲|ABBV234.85+4.84 (+2.10%) ▲|ABT90.75+2.92 (+3.32%) ▲|ACN126.82+1.99 (+1.59%) ▲|ADBE199.47+4.57 (+2.34%) ▲|AMAT586.25-53.93 (-8.42%) ▼|AMD520.90-30.73 (-5.57%) ▼|AMGN347.78+3.06 (+0.89%) ▲|AMT178.42+1.99 (+1.13%) ▲|AMZN234.44+1.65 (+0.71%) ▲|AVGO383.75-8.39 (-2.14%) ▼|AXP337.06-1.01 (-0.30%) ▼|BA218.49-2.34 (-1.06%) ▼|BAC57.79+0.42 (+0.72%) ▲|BKNG169.51+1.74 (+1.04%) ▲|BLK1,020.11-31.64 (-3.01%) ▼|BMY55.68+0.98 (+1.79%) ▲|BNY147.89+1.45 (+0.99%) ▲|BRK-B493.60+4.91 (+1.00%) ▲|C145.37-0.30 (-0.21%) ▼|CAT989.58-32.71 (-3.20%) ▼|CL91.38+2.71 (+3.05%) ▲|CMCSA22.89+0.57 (+2.53%) ▲|COF198.39-2.31 (-1.15%) ▼|COP110.28+0.58 (+0.52%) ▲|COST961.01+9.66 (+1.02%) ▲|CRM154.87+4.75 (+3.16%) ▲|CSCO121.81+0.28 (+0.23%) ▲|CVS101.33+0.03 (+0.03%) ▲|CVX176.14+1.08 (+0.61%) ▲|DE598.59+0.00 (+0.00%) ▲|DHR178.54+0.35 (+0.20%) ▲|DIS103.44+0.99 (+0.96%) ▲|DUK125.06+1.54 (+1.25%) ▲|EMR144.51-5.71 (-3.80%) ▼|FDX323.30-5.48 (-1.67%) ▼|GD349.10+5.74 (+1.67%) ▲|GE357.08+1.96 (+0.55%) ▲|GEV1,048.85-78.74 (-6.98%) ▼|GILD125.78+0.91 (+0.73%) ▲|GM80.08-0.35 (-0.44%) ▼|GOOG346.84-1.95 (-0.56%) ▼|GOOGL347.35-2.21 (-0.63%) ▼|GS1,099.08-7.29 (-0.66%) ▼|HD325.50-1.13 (-0.34%) ▼|HON224.66-3.46 (-1.51%) ▼|IBM265.84+13.62 (+5.40%) ▲|INTC133.70-7.24 (-5.14%) ▼|INTU260.76+2.99 (+1.16%) ▲|ISRG401.54-1.42 (-0.35%) ▼|JNJ237.14+5.85 (+2.53%) ▲|JPM334.13+2.65 (+0.80%) ▲|KO79.93+0.40 (+0.50%) ▲|LIN517.00+0.29 (+0.06%) ▲|LLY1,104.37+2.29 (+0.21%) ▲|LMT502.25+8.65 (+1.75%) ▲|LOW214.90+0.50 (+0.23%) ▲|LRCX370.97-38.57 (-9.42%) ▼|MA488.32+4.23 (+0.87%) ▲|MCD271.75+1.65 (+0.61%) ▲|MDLZ60.66+1.15 (+1.92%) ▲|MDT80.36+1.09 (+1.38%) ▲|META564.45+0.60 (+0.11%) ▲|MMM162.40-0.82 (-0.50%) ▼|MO71.12+1.61 (+2.32%) ▲|MRK118.74+3.26 (+2.82%) ▲|MS227.48+0.39 (+0.17%) ▲|MSFT372.72+5.38 (+1.46%) ▲|MU1,072.68-138.70 (-11.45%) ▼|NEE86.58+0.50 (+0.58%) ▲|NFLX73.19+0.31 (+0.42%) ▲|NKE42.94-0.25 (-0.58%) ▼|NOW97.36+4.35 (+4.67%) ▲|NVDA201.83-6.82 (-3.27%) ▼|ORCL168.27-6.80 (-3.88%) ▼|PEP141.06+0.35 (+0.25%) ▲|PFE25.01-0.08 (-0.30%) ▼|PG150.60+2.92 (+1.98%) ▲|PLTR118.86-0.64 (-0.54%) ▼|PM177.91+4.74 (+2.74%) ▲|QCOM201.15-20.75 (-9.35%) ▼|RTX184.92+3.09 (+1.70%) ▲|SBUX100.89+0.74 (+0.74%) ▲|SCHW93.03+1.00 (+1.09%) ▲|SO94.60+1.17 (+1.25%) ▲|SPG216.71+2.14 (+1.00%) ▲|T22.87+0.77 (+3.48%) ▲|TMO466.82+2.81 (+0.61%) ▲|TMUS183.26+3.20 (+1.78%) ▲|TSLA384.06-20.99 (-5.18%) ▼|TXN302.80-29.48 (-8.87%) ▼|UBER70.55-0.88 (-1.23%) ▼|UNH407.91+1.23 (+0.30%) ▲|UNP260.49+0.58 (+0.22%) ▲|UPS106.18-1.06 (-0.99%) ▼|USB59.74+1.06 (+1.81%) ▲|V331.10+4.50 (+1.38%) ▲|VZ46.60+1.24 (+2.73%) ▲|WFC83.83-0.01 (-0.01%) ▼|WMT119.53+2.35 (+2.01%) ▲|XOM140.15+1.68 (+1.21%) ▲|AAPL299.11+2.10 (+0.71%) ▲|ABBV234.85+4.84 (+2.10%) ▲|ABT90.75+2.92 (+3.32%) ▲|ACN126.82+1.99 (+1.59%) ▲|ADBE199.47+4.57 (+2.34%) ▲|AMAT586.25-53.93 (-8.42%) ▼|AMD520.90-30.73 (-5.57%) ▼|AMGN347.78+3.06 (+0.89%) ▲|AMT178.42+1.99 (+1.13%) ▲|AMZN234.44+1.65 (+0.71%) ▲|AVGO383.75-8.39 (-2.14%) ▼|AXP337.06-1.01 (-0.30%) ▼|BA218.49-2.34 (-1.06%) ▼|BAC57.79+0.42 (+0.72%) ▲|BKNG169.51+1.74 (+1.04%) ▲|BLK1,020.11-31.64 (-3.01%) ▼|BMY55.68+0.98 (+1.79%) ▲|BNY147.89+1.45 (+0.99%) ▲|BRK-B493.60+4.91 (+1.00%) ▲|C145.37-0.30 (-0.21%) ▼|CAT989.58-32.71 (-3.20%) ▼|CL91.38+2.71 (+3.05%) ▲|CMCSA22.89+0.57 (+2.53%) ▲|COF198.39-2.31 (-1.15%) ▼|COP110.28+0.58 (+0.52%) ▲|COST961.01+9.66 (+1.02%) ▲|CRM154.87+4.75 (+3.16%) ▲|CSCO121.81+0.28 (+0.23%) ▲|CVS101.33+0.03 (+0.03%) ▲|CVX176.14+1.08 (+0.61%) ▲|DE598.59+0.00 (+0.00%) ▲|DHR178.54+0.35 (+0.20%) ▲|DIS103.44+0.99 (+0.96%) ▲|DUK125.06+1.54 (+1.25%) ▲|EMR144.51-5.71 (-3.80%) ▼|FDX323.30-5.48 (-1.67%) ▼|GD349.10+5.74 (+1.67%) ▲|GE357.08+1.96 (+0.55%) ▲|GEV1,048.85-78.74 (-6.98%) ▼|GILD125.78+0.91 (+0.73%) ▲|GM80.08-0.35 (-0.44%) ▼|GOOG346.84-1.95 (-0.56%) ▼|GOOGL347.35-2.21 (-0.63%) ▼|GS1,099.08-7.29 (-0.66%) ▼|HD325.50-1.13 (-0.34%) ▼|HON224.66-3.46 (-1.51%) ▼|IBM265.84+13.62 (+5.40%) ▲|INTC133.70-7.24 (-5.14%) ▼|INTU260.76+2.99 (+1.16%) ▲|ISRG401.54-1.42 (-0.35%) ▼|JNJ237.14+5.85 (+2.53%) ▲|JPM334.13+2.65 (+0.80%) ▲|KO79.93+0.40 (+0.50%) ▲|LIN517.00+0.29 (+0.06%) ▲|LLY1,104.37+2.29 (+0.21%) ▲|LMT502.25+8.65 (+1.75%) ▲|LOW214.90+0.50 (+0.23%) ▲|LRCX370.97-38.57 (-9.42%) ▼|MA488.32+4.23 (+0.87%) ▲|MCD271.75+1.65 (+0.61%) ▲|MDLZ60.66+1.15 (+1.92%) ▲|MDT80.36+1.09 (+1.38%) ▲|META564.45+0.60 (+0.11%) ▲|MMM162.40-0.82 (-0.50%) ▼|MO71.12+1.61 (+2.32%) ▲|MRK118.74+3.26 (+2.82%) ▲|MS227.48+0.39 (+0.17%) ▲|MSFT372.72+5.38 (+1.46%) ▲|MU1,072.68-138.70 (-11.45%) ▼|NEE86.58+0.50 (+0.58%) ▲|NFLX73.19+0.31 (+0.42%) ▲|NKE42.94-0.25 (-0.58%) ▼|NOW97.36+4.35 (+4.67%) ▲|NVDA201.83-6.82 (-3.27%) ▼|ORCL168.27-6.80 (-3.88%) ▼|PEP141.06+0.35 (+0.25%) ▲|PFE25.01-0.08 (-0.30%) ▼|PG150.60+2.92 (+1.98%) ▲|PLTR118.86-0.64 (-0.54%) ▼|PM177.91+4.74 (+2.74%) ▲|QCOM201.15-20.75 (-9.35%) ▼|RTX184.92+3.09 (+1.70%) ▲|SBUX100.89+0.74 (+0.74%) ▲|SCHW93.03+1.00 (+1.09%) ▲|SO94.60+1.17 (+1.25%) ▲|SPG216.71+2.14 (+1.00%) ▲|T22.87+0.77 (+3.48%) ▲|TMO466.82+2.81 (+0.61%) ▲|TMUS183.26+3.20 (+1.78%) ▲|TSLA384.06-20.99 (-5.18%) ▼|TXN302.80-29.48 (-8.87%) ▼|UBER70.55-0.88 (-1.23%) ▼|UNH407.91+1.23 (+0.30%) ▲|UNP260.49+0.58 (+0.22%) ▲|UPS106.18-1.06 (-0.99%) ▼|USB59.74+1.06 (+1.81%) ▲|V331.10+4.50 (+1.38%) ▲|VZ46.60+1.24 (+2.73%) ▲|WFC83.83-0.01 (-0.01%) ▼|WMT119.53+2.35 (+2.01%) ▲|XOM140.15+1.68 (+1.21%) ▲|
20.6 C
New York
Tuesday, June 23, 2026

Tag: medicine

newssourceFORcompanyinformationcontent1marketreleases

Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer’s disease

The opinion will now be referred to the European Commission for final regulatory decision on donanemab  INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and...

MALAYSIA HEALTHCARE TRAVEL COUNCIL LAUNCHES MYMT 2026, MALAYSIA’S FIRST MEDICAL TOURISM YEAR

KUALA LUMPUR, Malaysia, July 25, 2025 /PRNewswire/ -- The Malaysia Healthcare Travel Council (MHTC)  launched Malaysia Year of Medical Tourism (MYMT) 2026 today at the...

MALAYSIA HEALTHCARE TRAVEL COUNCIL LAUNCHES MYMT 2026, MALAYSIA’S FIRST MEDICAL TOURISM YEAR

KUALA LUMPUR, Malaysia, July 25, 2025 /PRNewswire/ -- The Malaysia Healthcare Travel Council (MHTC)  launched Malaysia Year of Medical Tourism (MYMT) 2026 today at the...

Memo Therapeutics AG Announces Phase II Trial Results for Potravitug in Kidney Transplant Recipients with BKPyV Infection

Schlieren / Zurich, Switzerland, 25 July, 2025 – Memo Therapeutics AG ("MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announced results from its Phase II clinical trial evaluating potravitug, a highly potent human BK polyomavirus (“BKPyV”)-neutralizing monoclonal antibody, for the treatment of BKPyV infection in kidney transplant recipients (“KTR”).

WesternU COMP-Northwest to be named Heatherington College of Osteopathic Medicine

LEBANON, Ore., July 24, 2025 /PRNewswire/ -- Western University of Health Sciences' College of Osteopathic Medicine of the Pacific-Northwest will be named the Heatherington...

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

Dr. Joel Berley Launches 2026 Scholarship to Empower Aspiring Medical Leaders Nationwide

PLANTATION, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Dr. Joel Berley, a nationally respected oral surgeon and founder of Plantation Oral Surgery, is pleased to announce the official launch of the 2026 application cycle for the Dr. Joel Berley Scholarship for Future Doctors. This prestigious academic grant reflects Dr. Berley’s enduring mission to identify and uplift undergraduate students who are poised to become catalysts for progress in medicine.

Sugar Land Medical Weight Loss Expert, Dr. Adelola Ashaye, Launches Metabolic Wellness & Healthy Weight Program at InTouch Primary Care

Dr. Adelola Ashaye has launched Metabolic Wellness & Healthy Weight Program at InTouch Primary Care, offering a personalized, medically guided approach to sustainable weight loss...

Merakris Therapeutics Spotlights Investigational New Drug, MTX-001, with Innovation Showcase Win at 2025 Advanced Wound Care Summit

MTX-001 recognized for its clinical and commercial potential for treating chronic non-healing venous leg ulcers (VLUs) 
MTX-001 recognized for its clinical and commercial potential for treating chronic non-healing venous leg ulcers (VLUs)

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors

PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.

Omniscient and The Jacobs Institute, Inc. Announce Strategic Partnership to Pioneer Clinical Connectomics

Omniscient and The Jacobs Institute launch Connectomics Innovation Program to advance stroke recovery and neurologic care with AI-enabled software.

Knee Replacement Surgery Market worth $16.17 billion in 2030 with 6.1% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 24, 2025 /PRNewswire/ -- The global Knee Replacement Surgery Market, valued at US$10.86 billion in 2023 stood at US$12.00 billion in 2025...

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma

The presentation will include data from over 90 patients in both the plaque brachytherapy and enucleation-eligible cohortsDarovasertib has received U.S. FDA Breakthrough Therapy Designation...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedicine

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers